Fumarate hydratase (FH) is a metabolic enzyme that is part of the Krebs cycle and reversibly catalyzes the hydration of fumarate to malate. Mutations of the FH gene have been associated with fumarate hydratase deficiency (FHD), hereditary leiomyomatosis and renal cell cancer (HLRCC), and other diseases. Currently, there are no high-quality small-molecule probes for studying human FH. To address this, we developed a quantitative high-throughput screening (qHTS) FH assay and screened a total of 57,037 compounds from in-house libraries in dose-response. While no inhibitors of FH were confirmed, a series of phenyl-pyrrolo-pyrimidine-diones were identified as activators of human FH. These compounds were not substrates of FH, were inactive in a malate dehydrogenase counterscreen, and showed no detectable reduction-oxidation activity. The binding of two compounds from the series to human FH was confirmed by microscale thermophoresis. The low hit rate in this screening campaign confirmed that FH is a "tough target" to modulate, and the small-molecule activators of human FH reported here may serve as a starting point for further optimization and development into cellular probes of human FH and potential drug candidates.
Introduction
Fumarate hydratase (FH) is an important metabolic enzyme in the Krebs cycle, which reversibly catalyzes the conversion of fumarate to malate (hydration). It is encoded by the FH gene, which produces two isoforms of protein by alternative splicing, a cytosolic form and a mitochondrial form. The mitochondrial form of FH contains an N-terminal mitochondrial targeting sequence, which is removed in the mitochondrion to generate the same protein as that in the cytoplasm. Despite decades of research, a detailed understanding of the mechanism of FH's biochemical activity remains a matter of debate. The active enzyme is a homotetramer in which each active site is made up of residues at the interface of three of the four subunits. 1 FH participates in adenosine triphosphate (ATP) production in mitochondria and the metabolism of amino acids and fumarate in cytoplasm.
There are more than 100 known mutations in the human FH gene. The most common type is missense (57%), followed by frameshifts and nonsense (27%), and other mutations. 2 Mutations of the FH gene lead to defects of the enzymatic activity either by indirectly compromising the integrity of the protein's core architecture or by directly affecting residues within the active site that regulate catalytic activity of the enzyme. 3 FH gene mutations have been mainly associated with two heritable diseases: fumarate hydratase deficiency (FHD) and hereditary leiomyomatosis and renal cell cancer (HLRCC). Homozygous germline mutations in the FH gene cause autosomal recessive FHD syndrome, which is characterized by early-onset hypotonia, profound psychomotor retardation, seizures, facial dysmorphism, and brain abnormalities. 4 Mutations of the FH gene severely impair the enzyme activity, which leads to the defect of energy production and the accumulation of fumarate, which is believed to be the cause of clinical symptoms. 5 Heterozygous germline mutations in the FH gene predispose individuals to HLRCC, characterized by benign leiomyomas of the skin and the uterus and early-onset type II papillary renal cell carcinoma. 6 In affected individuals, loss of heterozygosity (LOH) in the wild-type allele by somatic mutations leads to severe reduction or absence of FH activity, which is followed by an increased intracellular level of fumarate. Accumulated fumarate acts as an oncometabolite to induce tumorigenesis through competitively inhibiting α-ketoglutaratedependent dioxygenase enzymes and posttranslationally modifying proteins by succination. 7, 8 Aside from FH deficiency and HLRCC, studies have also shown that FH is involved in hypertension, type 2 diabetes, and diabetic kidney disease. [9] [10] [11] For example, deletion of FH in mouse pancreatic β cells leads to progressive glucose intolerance and diabetes after 6-8 weeks. In humans, the fumarate level is higher in islets from donors with type 2 diabetes than from normal donors, and high glucose produces no further increase of fumarate. 11 Rescue of defected fumarase activity by re-expression of a normal FH gene could restore the fumarate level and respiratory function of mitochondria, 12, 13 which suggests that FH is a potential therapeutic target. The activators of fumarase would enhance the conversion of fumarate to malate, which may rescue the defect of FH. Currently, there are no biochemically characterized activators or inhibitors of FH. Two series of inhibitors have been reported to inhibit the activity of human 14 or Mycobacterium tuberculosis FH. 15 In an attempt to identify nutrient-dependent cytotoxic compounds, Takeuchi et al. 14 screened a collection of 6000 small molecules and discovered a new class of inhibitors of human FH (compounds 1-3 with pyrrolidinone structure). In another report, Kasbekar 15 reported that two inhibitors (compounds 7 and 8) were identified for M. tuberculosis fumarate hydratase (tbFH) after screening a collection of 479,984 small molecules.
To identify small-molecule activators or inhibitors of human FH, we developed a fluorescence-based FH assay by coupling to malate dehydrogenase (MDH)-diaphoraseresazurin and optimized the assay for quantitative highthroughput screening (qHTS) in 1536-well plates. We proceeded to screen a collection of small-molecule libraries to identify new activators or inhibitors of human FH. A total of 57,037 small-molecule compounds were screened, and the majority of hits were triaged by MDH counterscreen assay. One series of the activators for human FH was confirmed and validated in the current study.
Materials and Methods

Reagents and Chemical Libraries
Recombinant human FH (with 6 histidine tag in the N-terminal of protein), dithiothreitol (DTT), and Hank's Balanced Salt Solution (HBSS) were purchased from Thermo Fisher Scientific (Waltham, MA). L-malate dehydrogenase from pig heart, diaphorase from Clostridium kluyveri, β-NAD (NAD + ), resazurin, Brij 35, sodium fumarate dibasic, malic acid, and horseradish peroxidase (HRP) were purchased from Sigma-Aldrich (St. Louis, MO). Fumarate hydratase-IN-2 was purchased from MedChem Express (Monmouth Junction, NJ). Compound 8 was purchase from Enamine (Monmouth Junction, NJ). Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) was purchased from Cayman Chemical (Ann Arbor, MI). Six libraries were screened: the Sytravon [a retired pharma screening collection that contains a diversity of novel small molecules; from the National Center for Advancing Translational Sciences (NCATS)], NPACT (NCATS Pharmacologically Active Chemical Toolbox; from NCATS), NPC (NCATS Pharmaceutical Collection; NCATS), 16 MIPE (Mechanism Interrogation Plate; NCATS), a kinase inhibitor library (an in-house collection of kinase inhibitors; NCATS), and LOPAC 1280 (Library of Pharmacologically Active Compounds; 1280 pharmacologically active compounds; Sigma-Aldrich).
High-Throughput Screen and Counterscreen
For the primary high-throughput screen, 3 µL of FH solution (containing 13.33 nM human FH, 13.33 IU/mL malic dehydrogenase, 0.2 mM NAD + , 0.067 mg/mL diaphorase, and 0.067 mM resazurin) in the assay buffer (50 mM Tris pH 8.0, 5 mM MgCl 2 , and 0.01% Brij 3) was dispensed into each well in a black solid-bottom 1536-well assay plate (Greiner Bio-One, Monroe, NC) using a BioRAPTR FRD (Flying Reagent Dispenser; Beckman Coulter, Brea, CA). A 1536-well Pintool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 20 nL of DMSO-solubilized compound (cherrypick plates) to each 1536-well assay plate. Each compound was screened at five concentrations: 15 nM, 151 nM, 1.5 µM, 15.4 µM, and 76.9 µM. Following compound transfer, plates were incubated at room temperature (RT) for 10 min. To initiate the reaction, 1 µL of substrate solution containing fumaric acid (160 µM) was dispensed via BioRAPTR FRD. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (excitation/emission, 525/598 nm) at 0 and 15 min. The exposure time is 1 s. Fluorescence from each well was normalized using enzyme-free and DMSO-treated control wells on each plate, and changes in fluorescence (∆RFU) were calculated using the difference in fluorescent signal for each well at 15 min versus 0 min.
The MDH counterscreen was adapted from the primary high-throughput screen protocol. Three microliters of MDH solution [containing 13.33 IU/ml malic dehydrogenase, 0.2 mM NAD + , 0.067 mg/mL diaphorase, and 0.067 mM resazurin in assay buffer (50 mM Tris pH 8.0, 5 mM MgCl 2 , and 0.01% Brij 3)] were dispensed in each well in the 1536well plate. Plates were incubated at RT for 10 min after compound transfer. To initiate the reaction, 1 µL of substrate solution containing malic acid (160 µM) was dispensed. Fluorescence was measured (ex540, em590 nm) at 0 and 5 min. The fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate, and ∆RFU was calculated using the difference in fluorescent signal for each well at 5 min versus 0 min.
The Reduction-Oxidation (Redox) Assay
The Amplex Red assay was used to detect the redox activity of small molecules. Briefly, 2.5 µL HBSS solution (1.26 mM CaCl 2 , 0.49 mM MgCl 2 , and 1 g/L D-glucose) was dispensed into each well in a black solid-bottom 1536-well assay plate. Twenty nanoliters of compounds were pinned into the plate, and the background fluorescence (RFU 0min ) was measured in the ViewLux (excitation/emission, 525/598 nm). Two and a half microliters freshly made 2× Amplex Red solution (100 µM Amplex Red, 200 µM DTT, and 2 U/mL HRP in 1× HBSS solution) were added to each well. After 15 min incubation at RT, fluorescence (RFU 15min ) was measured in the ViewLux with the same setting. Redox activity of each compound was calculated using corrected fluorescence values (ΔRFU = RFU 15min − RFU 0min ). The negative control was DMSO, and the positive controls were walrycin B and chlorinal.
Microscale Thermophoresis (MST)
Recombinant human FH, which contains a polyhistidine tag at the C-terminus, was labeled with Monolith His-Tag Labeling Kit RED-tris-NTA kit (NanoTemper Technologies, Munich, Germany). Briefly, the protein was diluted to 200 nM in a phosphate-buffered saline and Tween (PBS-T) buffer (137 mM NaCl, 2.5 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , and pH 7.4 in 0.05% Tween-20). The RED-tris-NTA dye was also diluted in PBS-T to 100 nM. The diluted protein and dye were mixed in a 1:1 volume ratio and incubated for 30 min at RT. After centrifuge 15,000 ×g for 10 min at 4 °C, the supernatant was transferred to a new tube and ready to use.
Compounds were serially diluted in DMSO (16 points, 1:2 dilutions, from 10 mM), and then further diluted 20 times in PBS-T buffer. Ten microliters of labeled protein and 10 µL diluted compounds were mixed and incubated at RT for 2-3 min. The samples were loaded in the standard treated capillaries and measured in a NanoTemper Monolith NT.115 LabelFree instrument (NanoTemper Technologies). The samples were measured at light-emitting diode (LED) power of 40%, and MST power of 40% and 60%. A laser-on time of 30 s and a laser-off time of 5 s were used in this experiment. Curve fitting was performed using GraphPad Prism 5 (La Jolla, CA).
In Vitro ADME Studies
The physicochemical and pharmacokinetics properties of compounds were measured using the following highthroughput in vitro assays: rat microsomal stability assay, parallel artificial membrane permeability assay (PAMPA), and aqueous kinetic solubility assays. The details of these assays are described in a previous study. 17 
qHTS Data Analysis
Analysis of compound concentration-response data was performed as previously described. 18 Briefly, raw plate reads for each titration point were first normalized relative to the no-enzyme control and DMSO-only wells as follows: % Activity = [(V compound -V DMSO ) / (V DMSO -V no enzyme )] × 100, where V compound denotes the compound well values, V no enzyme denotes the median values of the no-enzyme control wells, and V DMSO denotes the median values of the DMSO-only wells; and then corrected by applying an NCATS Chemical Genomics Center (NCGC) in-house pattern correction algorithm using compoundfree control plates (i.e., DMSO-only plates) at the beginning and end of the compound plate stack. 19 Concentration-response titration points for each compound were fitted to a four-parameter Hill equation 20 yielding concentrations of half-maximal activity (AC 50 ) and maximal response (efficacy) values. Compounds were designated as Classes 1-4 according to the type of concentration-response curve observed. 18, 21 Curve classes are heuristic measures of data confidence, classifying concentration-responses on the basis of efficacy, the number of data points observed higher than background activity, and the quality of fit. Compounds with curve classes 1.1, 1.2, 2.1, 2.2 (activators) and −1.1, −1.2, −2.1, or −2.2 (inhibitors) were considered active. Class 4 compounds were considered inactive. Compounds with other curve classes were deemed inconclusive. Active compounds were cherrypicked for follow-up experiments.
Results
Assay Design, Optimization, and Miniaturization
To identify activators or inhibitors of human FH, we developed a fluorescence-based FH assay, adapted from a previous study. 15 In our assay format, the FH reaction is coupled to two sequential enzymatic reactions: MDH and diaphorase reactions. In the first coupled MDH reaction, L-malate produced by FH is converted into oxaloacetate, removing L-malate from the system and driving the FH forward reaction. The reduced form of nicotinamide adenine dinucleotide (NADH) generated by MDH is used in the second coupled reaction by diaphorase to convert resazurin to resorufin ( Fig. 1A) , with the further benefit of regenerating NAD + to drive the MDH biochemical reaction. Resorufin is strongly fluorescent, with an excitation wavelength at 530-540 nm and emission at 585-595 nm. 22, 23 Therefore, FH activity can be evaluated by measuring fluorescence signals of resorufin.
To optimize assay conditions, the initial linear velocity of the enzymatic reaction was determined in the presence of excess fumarate. We found that the enzymatic reaction was linear during a period of 30 min at a concentration of up to 20 nM FH enzyme ( Fig. 1B) . We selected a concentration of 10 nM FH enzyme and monitored the reaction for 15 min at RT (incubations not amenable to a high-throughput platform) for the remaining experiments. The K m value of fumarate was determined as 41 ± 1.1 µM by monitoring reaction kinetics in a wide range of fumarate concentrations (Fig. 1C) . Because we sought to identify both activators and inhibitors, the FH assay was performed with a substrate concentration near the K m value of fumarate (40 µM). A known liability of coupled enzymatic assays is that small molecules appearing to be active from high-throughput screening (HTS) may in fact be modulating the activity of MDH or diaphorase, rather than the target itself. To enable the triage of false positives, we developed an MDH counterassay, omitting FH and adding the MDH substrate malate to initiate the reaction. The kinetics of the MDH counterassay were evaluated at variable concentrations of MDH enzyme and at several time points. The biochemical reaction was found to be in the linear range for the first 5-6 min at concentrations up to 20 IU/mL MDH enzyme (Fig. 1D) . The K m value of malate was determined by the MDH assay as 225 ± 30 µM ( Fig. 1E) . This concentration of malate was selected for the MDH counterassay.
To assess the reproducibility and robustness of the assay, the FH assay was performed in white solid-bottom 1536well Greiner microplates, and statistics were analyzed. Buffer containing enzyme was dispensed into a microplate for columns 1, 2, and 5-48. The reagent without FH enzyme was dispensed into columns 3 and 4 as an enzyme-free negative control. DMSO (20 nL) was transferred into all wells, then incubated with enzyme for 10 min. The reaction was then initiated by adding fumarate. The kinetics of reaction was measured at t = 0 min and t = 15 min ( Table 1) . As shown in Figure 1F , the signal-to-background (S/B) ratio was 13.8, coefficient of variation was 6.1%, and Z' factor was 0.83. The assay conditions result in less than 10% substrate conversion during the course of the assay. To ensure the assay is amenable to storage of reagents during the multiple hours that a qHTS assay would require for initiation, enzymatic activity was assessed throughout storage times. FH was found to be unstable when stored at RT, rapidly losing activity within 2 h, but it was quite stable when stored on ice for at least 6 h (Suppl. Fig. 1 ).
qHTS Screening and Counterscreen
We screened six in-house libraries with a total number of 57,037 small-molecule compounds in 1536-well format ( Fig. 2A) . The libraries include the LOPAC 1280 ; the NPC, which covers 2816 compounds from late-stage clinical trials and U.S. Food and Drug Administration (FDA)approved drugs; the NPACT, which contains 5099 annotated compounds with known targets or biological pathways; the MIPE collection with 1912 oncology-focused compounds with well-annotated primary mechanisms of action; a kinase inhibitor-focused library with 977 compounds; and a smallmolecule screening collection with diverse scaffolds designed from novel chemical space (44,953 compounds). The assay was robust and consistent throughout the screening plates, with an average assay Z' factor of 0.73 ± 0.09 (Fig. 2B) . The hit rate of activators was 0.1% (69 compounds), and of inhibitors was 1.5% (868 compounds). The qHTS data were deposited in PubChem with assay identification (AID) 1347055, and the assay is accessible via the following link: https://pubchem.ncbi.nlm.nih.gov/assay/ assay.cgi?aid=1347055. We cherrypicked 374 compounds based on our selection criteria (active compounds and efficacy ≥50%; see Materials and Methods) for confirmation testing. In the confirmation assay, 13 compounds were confirmed as active activators, and 178 as active inhibitors. The majority of the confirmed hits displayed activity in the MDH counterassay, however, and were triaged.
Only four series of inhibitors and two series of activators survived the counterscreening process. We then plated a total of 166 analogs structurally related to the hits from our in-house library for retesting. One series of activators was confirmed in our FH assay (Fig. 3A) and further evaluated in the follow-up experiments. All other compounds dropped out during the reconfirmation assays.
Identification and Validation of FH Activators
The activator chemotype is composed of a series of phenyl-pyrrolo-pyrimidine-diones, which are active against FH with AC 50 ranging from 5.6 µM to 31.6 µM and efficacy ranging from 35% to 79% ( Table 2) . Compounds were not active in the MDH counterassay (Fig. 3B) . No signal was detected in the absence of substrates in both assays (Fig. 4A) , which indicated neither compound was the substrate of those two enzymes (unlike tartrate, vide infra). To ensure activity was not due to impurities in the library material, four compounds (highest potency and efficacy) were purchased from vendors and purified via reverse-phase high-performance liquid chromatography (HPLC). The newly acquired compounds showed similar activity (Suppl. Fig. 2) .
Artefactual liabilities of screening hits can be responsible for the apparent activation, such as the ability to undergo redox cycling. The activator chemotype we identified contains a pyrimidine-2,4(3H)-dione motif. This is not expected to participate in redox chemistry, but it is prudent to de-risk such artefactual activity even if it is not expected. This is especially true when coupled assays such as the one described here use oxidoreductive conversions between NAD + and NADPH to facilitate assay readout. To examine whether compounds have redox activity, the Amplex Red assay was performed. In the assay, two compounds with weak (walrycin B) and strong (chloranil) redox activity were used as positive controls. None of the hit compounds displayed detectible redox activity (Fig. 4B) .
We performed MST as a biophysical assay to directly demonstrate binding of activators to FH. 24 Two compounds with high potency, NCGC00102736 (AC 50 = 8.89 µM) and NCGC00117675 (AC 50 = 9.98 µM), were evaluated. The dissociation constant (K d ) of NCGC00102736 was found to be 18.3 µM, and of NCGC00117675 was 23.3 µM (Fig. 5) .
In Vitro ADME Properties of FH Activators
To evaluate the physicochemical and pharmacokinetic properties of the FH activator series, we selected the four most potent compounds and tested them in a series of in vitro ADME assays. Using automated high-throughput in vitro assays, we examined the rat microsomal metabolic stability, permeability, and solubility in those compounds ( Table 3 ). The half-life (t 1/2 ) of compounds in the rat hepatic microsomal stability assay ranged from 1.1 min to 7.7 min, suggesting that these compounds were metabolically unstable. The PAMPA was used as an in vitro model of passive, transcellular permeation. Two pH conditions (pH 5 and pH 7.5) were tested in this assay. All compounds scored as highly permeable (>100 × 10 6 cm/s) at pH 5, and two compounds (NCGC00102736 and NCGC00117675) showed high permeability at pH 7.4. Aqueous solubility was assessed by a high-throughput kinetic solubility assay. The solubility value ranged from <1 µg/mL to 14.7 µg/mL, indicating these compounds had low aqueous solubility.
Evaluation of Prior Art Compounds and Artifacts
Because two inhibitors of FH were reported previously, we evaluated the activity of those inhibitors in our human FH assay. We resynthesized compound 3 (fumarate hydratase-IN-2), which had been reported as active against human FH in a commercial in vitro assay (K i = 4.5 µM). 14 We found compound 3 to be inactive in our biochemical assay . The hit rate of the primary screen is shown in the left panel, and the hit rate of the confirmation screen is shown in the right panel.
( Fig. 6A) . Based on the core structure of compound 3, we further cherrypicked 68 analogs of this chemotype and found none of them were active in our FH assay (data not shown). There are multiple reasons for not being able to reproduce the activity of compound 3. For example, the FH inhibition by compound 3 was demonstrated with a commercial biochemical kit, and it is possible that the compound also affected other components of the kit assay system. In another report, Kasbekar 15 reported two inhibitors of tbFH from the same chemotype (compounds 7 and 8 in their article). We tested compound 8, which showed weak inhibitory activity at the highest concentration (IC 50 = 42.2 µM; efficacy = 30.2%) in our human FH assay (Fig. 6A) . Given that enzymes from the two species share identical residues in active sites and overall 59% similarity, 25 it is not surprising that compound inhibitors targeting tbFH also showed a weak inhibitory activity against human FH. During our HTS campaign, we identified an interesting false-positive compound, U-50488, which is a highly selective κ-opioid agonist. There are three salt forms of U-50488 in our collection. We found that the tartrate salt of U-50488 showed very high activator activity. However, the hydrochloride and methanesulfonate salts of U-50488, which are also in our library, showed no activator activity (Fig. 6B) . We speculated that this activator activity might derive from the tartrate salt component instead of compound U-50488 itself. Potassium sodium tartrate was then tested and was In the heat map, each row represents a compound, and each column represents an assay readout. The left column is the fumarase assay, and the right column is the malate dehydrogenase (MDH) assay. Each cluster of compounds is labeled by the most significantly enriched Medical Subject Headings (MeSH) pharmacological action (PA) term in that cluster measured by a Fisher's exact test. The colors in the heat map represent the activity of the compound, ranging from blue (inhibitors) to red (activators). (B) Dose-response curve of one series of activators (12 compounds) . The x-axis is the logarithmic scale of compound concentration, and the y-axis is the efficacy (%activity) of the compounds. Red curves represent the data from the fumarate hydratase (FH) assay, and gray curves represent the data from the MDH counterassay. The NCATS Chemical Genomics Center (NCGC) number is the sample identification number of each compound in our library. confirmed to produce increased activity in our FH assay ( Fig. 6C) . Because tartrate was reported as a substrate of FH and MDH in the 1960s, 26, 27 we hypothesized that tartrate might be used as the substrate of FH or MDH in our assays, giving the appearance of activation. To test this hypothesis, we serially diluted tartrate and added it to FH or MDH assays without their normal substrate (fumarate or malate) in the reaction. We found that tartrate can drive both enzymes in the absence of their eponymous substrates with a similar reaction rate ( Fig. 6D and 6E) . The K m value of tartrate was determined by the MDH assay to be K m = 1296 ± 33 µM (Fig. 6F) , much higher than malate, the normal substrate of MDH (K m = 225 ± 30 µM). The finding here is a reminder that the salt composition of compounds can be an interference in an enzymatic assay, which we need to be cautious of in future HTS campaigns. Certainly, this is not an artifact the authors were alert to prior to this study, and the fact that our libraries contained multiple salts of the same compound greatly aided in recognizing the possible cause of the artifact.
Discussion
In our efforts to identify small-molecule probes for FH, we developed a qHTS FH assay and screened a collection of small-molecule libraries. After several rounds of screening and counterscreening, only one series of activators met all activity criteria in our study. Those compounds were not substrates of FH, and they demonstrated direct binding to FH protein. This activator series enhanced the FH activity in the presence of its substrate. Our results suggest that these compounds are allosteric modulators of FH; however, further work is needed to optimize activity and confirm their mechanism of activation. The series identified as FH activators is a group of phenyl-pyrrolo-pyrimidine-diones ( Fig. 2A and Fig. 3B) . The hit series consists of 12 active compounds and 9 inactive compounds. A structure-activity relationship (SAR) analysis with this limited set of compounds suggested that the nature of the substitution on the pyrrole nitrogen (R) was important for FH activation (Suppl. compounds appeared to favor the attachment of a methylene unit to the pyrrole nitrogen, followed by further substitution (see Fig. 2A ). Attachment of additional substituents to this carbon, for example when R was branched such as a phenyl ring or a secondary or tertiary alkyl group, led to erosion in activity. Linear alkyl, phenethyl, and benzyl substituents on the pyrrole N were well tolerated. These data suggest that the pyrrole nitrogen might be important for the compound's interaction with the protein target and that an uncrowded environment around it might be essential for its binding to the target. With regard to the 5-phenyl ring, the presence of a halide substitution (X = Cl or Br) appeared to be necessary for activity (Suppl . Table 1) , because a compound (NCGC00141286) with a long alkyl R but no phenyl ring substitution was inactive. With only one exception, all active compounds in the series have a halogen in the para or ortho position. This information and medicinal chemistry efforts could further improve the chemotype's potency against fumarase. Pan-assay interference compounds (PAINS) are the compounds shown as false positives in high-throughput screens. 28 To exclude fluorescent compounds, we used change of fluorescence (ΔRFU) as the readout. If compounds are fluorescent, the signal should not change throughout the time (15 min in our assay), and the value of ΔRFU should be close to zero. To filter out the compounds interacting with coupled enzymes in the assay (MDH and diaphorase), a MDH assay was used as a counterassay to triage these falsepositive compounds. The MDH counterassay may, however, triage compounds that inhibit or activate both FH and MDH. As a common substrate for both FH and MDH, malate should be able to bind to the active sites of both enzymes, which suggests a structural similarity in active sites between two enzymes. The inhibitors that competitively bind to the same active sites will be filtered out in the MDH counterassay. As such, nonselective competitive inhibitors would be prone to exclusion by assay format. No inhibitors were identified in the current study after screening a collection of 57,037 compounds. In a similar assay format, Kasbekar 15 also didn't identify any competitive inhibitors for tbFH after screening a collection of 479,984 compounds. Instead, two inhibitors that bind to an allosteric regulatory site were found.
In summary, we developed a quantitative high-throughput screening FH assay and screened a collection of 57,037 small molecules. A series of phenyl-pyrrolo-pyrimidine-diones were identified as activators of human FH, which can serve as a starting point for further optimization and development as probes for the enzyme.
